AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer

CompletedOBSERVATIONAL
Enrollment

541

Participants

Timeline

Start Date

September 23, 2019

Primary Completion Date

February 22, 2022

Study Completion Date

July 22, 2022

Conditions
Colorectal Cancer Stage IV
Interventions
DIAGNOSTIC_TEST

Immunohistochemistry

Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.

Trial Locations (7)

Unknown

Calderdale and Huddersfield NHS Foundation Trust, Huddersfield

LS9 7TF

St James's University Hospital, Leeds

M20 4BX

The Christie NHS Foundation Trust, Manchester

CH63 4JY

The Clatterbridge Cancer Centre, Metropolitan Borough of Wirral

NE7 7DN

The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

NG7 2UH

Nottingham University Hospitals NHS Trust, Nottingham

S5 7AU

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

All Listed Sponsors
collaborator

University of Liverpool

OTHER

collaborator

University of Manchester

OTHER

collaborator

Newcastle University

OTHER

collaborator

University of Nottingham

OTHER

collaborator

University of Sheffield

OTHER

lead

University of Leeds

OTHER

NCT03986541 - AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer | Biotech Hunter | Biotech Hunter